FMP
Silexion Therapeutics LTD
SLXN
NASDAQ
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
1.03 USD
0.3144 (30.52%)
Retained Earning Schedule
Year
2024
2023
Retained Earnings (Previous Year)
-26.81M
-21.87M
Net Income
16.51M
-4.94M
Stock Repurchases
0
0
Dividend Paid
0
0
Retained Earnings
-43.25M
-26.81M
Other Distributions
-16.44M
-4.94M
All figures are in USD.
